Finance

Beta
Lists
RGNX:NASDAQ
Regenxbio Inc
$9.62
+6.06%
(+0.55) 1D
Jun 23, 10:18:34 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RGNX...
Open
$8.94
High
$9.79
Low
$8.94
Mkt. cap
501.47M
Avg. vol.
2.34M
Volume
604.10K
52-wk high
$16.19
52-wk low
$5.46
EPS
-$5.59
Beta
1.04
Shares outstanding
51.70M
No. of employees
371
Open
$8.94
High
$9.79
Low
$8.94
Mkt. cap
501.47M
Avg. vol.
2.34M
Volume
604.10K
52-wk high
$16.19
52-wk low
$5.46
EPS
-$5.59
Beta
1.04
Shares outstanding
51.70M
No. of employees
371
News stories
From sources across the web
About Regenxbio Inc
CEO-
Employees371
Founded2008
HeadquartersRockville, Maryland, United States
SectorBiotechnology
Websiteregenxbio.com
Analyst Ratings
Based on 9 analysts giving stock ratings to RGNX in the past 3 months
Strong Buy
Buy
8
Hold
1
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for RGNX in the last 3 months.
Highest
Current $9.62
$42.00 (+336.59%)
Average
$20.89 (+117.15%)
Lowest
$10.00 (+3.95%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Brian Skorney
Robert W. Baird
Buy
Maintained
$32.00
+232.6%
06/23/2026
Yi Chen
H.C. Wainwright
Buy
Reiterated
$26.00
+170.3%
06/23/2026
Annabel Samimy
Stifel Nicolaus
Buy
Reiterated
$42.00
+336.6%
05/27/2026
Mani Foroohar
Leerink Partners
Buy
Maintained
$17.00
+76.7%
05/15/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$16.00
+66.3%
05/15/2026
Luca Issi
RBC Capital
Buy
Maintained
$19.00
+97.5%
05/14/2026
Paul Choi
Goldman Sachs
Hold
Maintained
$10.00
+4%
05/14/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$14.00
+45.5%
05/14/2026
Eliana Merle
Barclays
Buy
Maintained
$12.00
+24.7%
05/15/2026
William Maughan
Clear Street
Buy
Reiterated
$45.00
+367.8%
03/06/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
$52.00
+440.5%
01/28/2026
Last report
May 14, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$1.72 / -$1.41
-21.64%miss
Revenue / Est. (USD)
6.39M / 25.25M
-74.68%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
21.36M
29.73M
30.34M
6.39M
Cost of goods sold
64.71M
61.83M
65.54M
68.41M
Cost of revenue
64.71M
61.83M
65.54M
68.41M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.88M
20.25M
22.38M
21.31M
Operating expense
19.93M
20.32M
22.43M
21.34M
Total operating expenses
84.64M
82.14M
87.97M
89.76M
Operating income
-63.28M
-52.41M
-57.64M
-83.36M
Other non operating income
-
-
-
-
EBT including unusual items
-70.87M
-61.94M
-67.15M
-90.05M
EBT excluding unusual items
-70.87M
-61.94M
-67.15M
-90.05M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
45.00K
65.00K
54.00K
36.00K
Net income
-70.87M
-61.94M
-67.15M
-90.05M
Net profit margin
-331.81%
-208.32%
-221.34%
-1,408.59%
Earnings per share
-1.38
-1.20
-1.30
-1.72
Interest and investment income
3.40M
3.64M
2.76M
2.02M
Interest expense
-10.99M
-13.17M
-12.28M
-8.71M
Net interest expenses
-7.59M
-9.53M
-9.51M
-6.69M
Depreciation and amortization charges
-
-
-
-
EBITDA
-59.37M
-48.52M
-53.77M
-79.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer